Nicole Basset‐Séguin

机构：Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Institut de recherche Saint-Louis · ORCID：0000-0002-9136-1244

发表论文 370 篇 · 总被引 11641 次 · h-index 53

代表论文

• European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024 (2024 · European Journal of Cancer · 被引 92)
• Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma (2025 · New England Journal of Medicine · 被引 82)
• European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024 (2024 · European Journal of Cancer · 被引 74)
• A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 (2024 · Journal of the American Academy of Dermatology · 被引 68)
• Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors (2023 · Critical Reviews in Oncology/Hematology · 被引 67)
• Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up (2023 · Journal of the American Academy of Dermatology · 被引 16)